Article Text

PDF
533 TREATMENT AND OUTCOMES OF MERKEL CELL CARCINOMA AT UCSF.
  1. C. Tan,
  2. M. Florero,
  3. S. P.L. Leong
  1. Department of Surgery, University of California San Francisco, San Francisco, CA

Abstract

Background Cyril Toker first described merkel cell carcinoma (MCC), a rare, aggressive, neuroendocrine carcinoma of the skin, in 1972.

Purpose The aim of our study is to review the UCSF experience of treating MCC from 1989 to the present time.

Method A retrospective study using a database of patients treated and followed at UCSF Hospitals.

Results There are 68 patients with MCC presenting on the head and neck (33), extremities (23), torso/trunk (3), vagina (1), parotid gland (1), and NOS (7). To date, 40 of 42 patients are still alive and disease free. The other 2 patients had recurrence as multiple distant metastasis and invasion into adjacent organs. At this time, additional clinical outcome information is being gathered.

Conclusion A significant number of patients had MCC in the head and neck region. The mortality rate of MCC at UCSF is 38.2% at the present time.

I would like to thank the University of British Columbia MD/PhD Program and CIHR for their support.

Statistics from Altmetric.com

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.